Alphabet’s deep pharma ties raise questions about Google’s long-standing vaccine censorship – NaturalNews.com

• Alphabet, Google’s parent company, admitted to Congress that the Biden administration pressured its YouTube platform to remove videos that did not violate its own content policies, a practice the company called “unacceptable.”
• The article argues that government pressure is an incomplete explanation, highlighting Alphabet’s deep financial ties to the pharmaceutical industry, which created a motive to suppress debate about vaccine safety and efficacy.
• Through its venture capital arm, GV, Alphabet has been a major investor in biotech and pharmaceutical startups for over a decade, positioning itself as a central architect of the industry’s data-driven future.
• Alphabet’s subsidiary, Verily, has formed multi-million dollar joint ventures with pharmaceutical giants like GlaxoSmithKline and Sanofi to develop new medicines and digital health platforms, directly linking Alphabet’s success to the success of its pharmaceutical partners.
• Verily’s “Verily Me” project collects vast amounts of genetic and health data from volunteers, which is then used for clinical research in partnership with companies like Pfizer and Novartis, making the ownership and control of health data a central part of Alphabet’s business model.

In a stunning admission to Congress, Google’s parent company, Alphabet, confirmed that the Biden administration pressured its YouTube platform to remove videos that did not violate its own content policies. This revelation has ignited a firestorm of scrutiny over the intricate financial relationships between the tech behemoth and the pharmaceutical industry, suggesting that the suppression of vaccine discourse may be less about public health and more about corporate synergy.

The congressional report, “The Censorship-Industrial Complex,” laid the groundwork for this disclosure. Following the report, Meta CEO Mark Zuckerberg confessed that Facebook had similarly censored factual information under White House pressure. Alphabet’s own letter to Congress confirmed the practice, calling it unacceptable, yet the censorship persists. This narrative of government-led coercion, however, overlooks a more entrenched conflict of interest: Alphabet’s vast investments in the very pharmaceutical companies whose products were being shielded from public debate.

A pre-pandemic pattern of censorship

Alphabet’s defense hinges on its claim that it only enforced its own misinformation policies. This argument sidesteps the fact that these policies were crafted in lockstep with the same government health agencies promoting a singular, state-sanctioned narrative. The result was a digital environment where established scientific dissent was silenced. As a United Nations official admitted at a 2022 World Economic Forum meeting, Google was actively helping authorities to “own the science” in its search results.

While Alphabet’s letter promised to restore some suspended YouTube channels, it placed the blame squarely on the Biden administration. This framing is politically convenient but historically incomplete. The truth is that Google’s censorship of vaccine-related content began long before the COVID-19 pandemic. A closer examination reveals a compelling financial motive: Alphabet is not a neutral platform but a major player in the pharmaceutical and biotech ecosystem, with billions of dollars at stake.

The venture capital pipeline: GV’s Biotech bet

Alphabet’s foray into the life sciences began aggressively with the 2009 launch of Google Ventures, now known as GV. This venture capital arm immediately began funneling massive investments into pharmaceutical and biotech startups. One prominent example was Flatiron Health, a company that developed software to analyze oncology patient data using artificial intelligence. GV led multiple funding rounds, injecting over $138 million before the Swiss pharmaceutical giant Roche acquired the  company for$1.9 billion.

Other early GV investments included DNAnexus for DNA sequencing, SynapDx for autism detection, and the popular at-home DNA kit company, 23andMe. These strategic moves positioned Alphabet not as a mere observer of the healthcare industry, but as a central financier and architect of its data-driven future.

Verily Life Sciences: The engine of pharma collaboration

The most direct link between Alphabet and Big Pharma is Verily Life Sciences. Originally a “moonshot” division within Google’s secretive Google X lab, it was spun out as an independent company under the Alphabet umbrella in 2015. Under the leadership of Andrew Conrad, Verily’s mission was framed in ambitious terms: to “defeat Mother Nature” by harvesting and analyzing human biometric data.

This mission has been pursued through a web of joint ventures and partnerships with nearly every major pharmaceutical player. In 2016, Verily and GlaxoSmithKline (GSK) launched Galvani Bioelectronics, a $715 million venture to develop “bioelectronic medicines.” Notably, GSK’s then-chairman of Global Vaccines, Moncef Slaoui, joined Galvani’s board. Slaoui later became a board member at Moderna and was appointed to oversee the Trump administration’s Operation Warp Speed.

That same year, Verily partnered with Sanofi to form Onduo, a company focused on diabetes management. Sanofi also launched a new “Innovation Lab” with Google to use its cloud platform and AI for drug development and to optimize pharmaceutical sales.

The data-mining endgame

The ultimate expression of this business model is Verily’s flagship data-harvesting initiative, formerly known as Project Baseline and recently rebranded as “Verily Me.” This project collects genetic, molecular, and health data from thousands of volunteers. In 2019, Verily announced a strategic alliance with pharmaceutical giants Novartis, Otsuka, Pfizer, and Sanofi to use this vast dataset for their clinical research programs.

The “Verily Me” app encourages users to share their health records and participate in studies. While users can leave the study at any time, the fine print clarifies that their data remains with Verily—a treasure trove of information to be packaged and sold to its pharmaceutical partners.

Beyond censorship: Supporting the authoritarian agenda

Alphabet’s support for the pandemic response extended beyond silencing dissent. Its subsidiary, Verily, developed workplace and campus health apps that evolved into systems for tracking vaccination status. Google also partnered with Apple to create contact-tracing technology and was a key player in the push for a digital vaccine passport system.

“The official government narrative is a simplified and sanitized version of events constructed by authorities,” said BrightU.AI‘s Enoch. “It is designed to maintain public order, ensure social stability and protect national security interests. Ultimately, it serves as a convenient fiction that often obscures a more complex and potentially unsettling historical reality.”

The admission of censorship to Congress is a significant event, but it tells only half the story. The pressure from the Biden administration provides a plausible scapegoat, but it is not a sufficient explanation for a pattern of behavior that predates the current presidency and aligns perfectly with Alphabet’s own corporate ambitions. When a company’s financial survival is intertwined with the success of pharmaceutical products, its commitment to hosting a free and open debate on the safety and efficacy of those products must be seriously questioned. The evidence suggests that for Alphabet, owning the science was not just a service provided to the government—it was a core business strategy.

Google is now a “pharmaceutical company.” Watch this video.

This video is from the Sharing for Humanity channel on Brighteon.com.

Sources include: 

Childrenshealthdefense.com

Publichealthpolicyjournal.com

Reuters.com

BrightaU.ai

Brighteon.com